Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the therapeutic effect of oral alitretinoin (Toctino®) in the treatment of CLE
with respect to proportion of responders based on the Revised Cutaneous Lupus Disease Area
and Severity Index (RCLASI) activity score for skin lesions at baseline and after 24 weeks of
treatment or at the latest assessment for patients who withdrew prematurely. Response is
defined as a reduction of 50% in the total RCLASI compared to the baseline value ("RCLASI
50").